PJP:NYE-Invesco Dynamic Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 87.28

Change

-0.02 (-0.02)%

Market Cap

N/A

Volume

4.10K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-29 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.41 (-0.28%)

USD 40.26B
FHLC Fidelity® MSCI Health Care In..

-0.09 (-0.13%)

USD 2.86B
FXH First Trust Health Care AlphaD..

+0.53 (+0.49%)

USD 1.18B
XHE SPDR® S&P Health Care Equipme..

+0.34 (+0.39%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.16 (+0.67%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

-0.09 (-0.24%)

USD 0.12B
XHS SPDR® S&P Health Care Service..

+1.33 (+1.42%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.05 (+0.16%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.26 (+0.41%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.14 (-0.47%)

USD 0.01B

ETFs Containing PJP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.69% 90% A- 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.69% 90% A- 70% C-
Trailing 12 Months  
Capital Gain 26.49% 67% D+ 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.49% 67% D+ 66% D+
Trailing 5 Years  
Capital Gain 46.12% 81% B- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.12% 81% B- 72% C
Average Annual (5 Year Horizon)  
Capital Gain 6.72% 67% D+ 59% D-
Dividend Return 7.30% 62% D 53% F
Total Return 0.58% 58% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 13.03% 76% C+ 71% C-
Risk Adjusted Return 55.99% 81% B- 73% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike